These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23307913)

  • 21. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout.
    Jiang H; Chappell R; Fine JP
    Control Clin Trials; 2003 Apr; 24(2):135-46. PubMed ID: 12689735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sample size in cluster-randomized trials with time to event as the primary endpoint.
    Jahn-Eimermacher A; Ingel K; Schneider A
    Stat Med; 2013 Feb; 32(5):739-51. PubMed ID: 22865817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.
    Sugimoto T; Hamasaki T; Evans SR; Halabi S
    Lifetime Data Anal; 2020 Apr; 26(2):266-291. PubMed ID: 30980317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral suppression in HIV studies: combining times to suppression and rebound.
    Gouskova NA; Cole SR; Eron JJ; Fine JP
    Biometrics; 2014 Jun; 70(2):441-8. PubMed ID: 24446693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints.
    Xu R; Mehrotra DV; Shaw PA
    Stat Med; 2018 Oct; 37(23):3280-3292. PubMed ID: 29888552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
    Żebrowska M; Posch M; Magirr D
    Stat Med; 2016 May; 35(12):1972-84. PubMed ID: 26694878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample size determination in clinical trials with multiple co-primary binary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    Stat Med; 2010 Sep; 29(21):2169-79. PubMed ID: 20687162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Power and sample size for randomized phase III survival trials under the Weibull model.
    Wu J
    J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics.
    Yang P; Fleming TR
    J Biopharm Stat; 2006; 16(2):241-52. PubMed ID: 16584070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
    Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
    J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.
    Gilbert PB; Ribaudo HJ; Greenberg L; Yu G; Bosch RJ; Tierney C; Kuritzkes DR
    AIDS; 2000 Sep; 14(13):1961-72. PubMed ID: 10997401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statistical considerations when using a composite endpoint for comparing treatment groups.
    Gómez G; Lagakos SW
    Stat Med; 2013 Feb; 32(5):719-38. PubMed ID: 22855368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Not too big, not too small: a goldilocks approach to sample size selection.
    Broglio KR; Connor JT; Berry SM
    J Biopharm Stat; 2014; 24(3):685-705. PubMed ID: 24697532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.
    Sozu T; Sugimoto T; Hamasaki T
    Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of matched pair designs with two binary endpoints.
    Jiang Y; Xu J
    Stat Methods Med Res; 2017 Dec; 26(6):2526-2542. PubMed ID: 26294329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.